Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213759 | 0.82 | FADS1 (0.42) | KMT2AALDH1A1KDM4EPOLBNPC1 | |
| SCHEMBL216074 | 0.81 | KDM4E (0.43) | KMT2AALDH1A1KDM4EPOLBNPC1 | |
| SCHEMBL213970 | 0.80 | SMN1; SMN2 (0.48) | KMT2AALDH1A1KDM4EPOLBRAB9A | |
| SCHEMBL216069 | 0.79 | MPO (0.47) | L3MBTL1KMT2AHTTALDH1A1KDM4E | |
| SCHEMBL214714 | 0.79 | MAPT (0.44) | L3MBTL1KMT2AHTTALDH1A1KDM4E | |
| SCHEMBL217153 | 0.78 | SOAT1 (0.40) | KMT2AHTTALDH1A1KDM4EMAPK1 | |
| SCHEMBL214789 | 0.78 | KDM4E (0.47) | L3MBTL1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL214872 | 0.78 | MAPT (0.42) | KMT2AALDH1A1KDM4EPOLBNPC1 | |
| SCHEMBL214646 | 0.77 | EPHB3 (0.44) | KMT2AHTTALDH1A1KDM4EPOLB | |
| SCHEMBL215132 | 0.77 | CYP3A4 (0.44) | L3MBTL1KMT2AHTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | BACE1 4486/4885BACE2 1591/4885L3MBTL1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.